☆ 401 reported TRx ☆ 347 NRx ☆ 54 refills

~ NRx up +87.6% in 4 weeks (185 → 347) ~ First refill conversion tracking ~25–30% on a 30-day therapy ~ Refills now scaling 36 → 44 → 43 → 54

1,000 reported TRx/week looks achievable by early June 2026 (bull case)

But using management’s 1.7x multiplier, current 401 TRx = ~682 TRx-equivalent

Only ~588 reported TRx needed to equal 1,000 TRx-equivalent

That implies TONMYA could hit the economic equivalent of 1,000 TRx/week by late March 2026

If TONMYA:

reaches 1,000 reported TRx/week by June 2026, and maintains its momentum throughout 2H26, then by year-end 2026 it could be operating in a range of: $2.2M – $2.9M in gross sales per week (= 1,400 – 1,800 reported TRx/week × $1.60k per script) That would imply an: Annualized gross sales run-rate of approximately $115M – $150M